Ancillary Symposium: New Horizons for Medical Management of Acromegaly
Not Currently Available
Landscape: What’s New and What’s Changed
Shlomo Melmed, MB ChB
Cedars-Sinai Medical Center, Los Angeles, California, USA
Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).

Disclosures:

Consultant, Chiasma Inc, Ionis, Crinetics, Ipsen; Research Grant Support, Pfizer
Expanding View: Understanding Patients’ Treatment Burden and Experience
Eliza B. Geer, MD
Memorial Sloan Kettering Cancer Center, New York, New York, USA
Eliza B. Geer, MD, joined the faculty at The Mount Sinai Medical Center in July, 2006 with an appointment in the Division of Endocrinology and a secondary appointment in the Department of Neurosurgery. After graduating from Columbia University, she attended Mount Sinai School of Medicine, graduating with Distinction in Research. She completed her Internship and Residency in Internal Medicine at Columbia Presbyterian Medical Center, where she became involved in neuroendocrine research, conducting studies on the hypothalamic-pituitary-adrenal axis and acromegaly. After completing her residency, she conducted a year of clinical research at Columbia's Obesity Research Center, funded by a NIH T32 grant, where she focused on body composition and appetite in acromegaly. She then completed a fellowship in Endocrinology, Diabetes and Bone Disease at the Mount Sinai Medical Center, graduating in 2006.

Disclosures:

Research Support, Novartis, Strongbridge, Chiasma, Ionis, Bristo-Myers Squibb; Consultant, Chiasma; Advisory Board, Strongbridge
A New Horizon: Treatment Options for Optimal Outcomes
Lawrence Katznelson, MD
Stanford School of Medicine, Stanford, California, USA
Laurence Katznelson, MD, received his medical degree from the University of California, Los Angeles and performed his internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania, Philadelphia. He then performed a fellowship in Endocrinology and Metabolism at the Massachusetts General Hospital, Boston. Dr. Katznelson is a Professor of Neurosurgery and Medicine at Stanford University School of Medicine. At Stanford University, he is the Associate Dean of Graduate Medical Education and the Chair of the GME Committee. Dr. Katznelson is currently the Medical Director of the Pituitary Center at Stanford Hospital and Clinics. In the Endocrine Society, Dr. Katznelson has served as Chair of the Special Programs and Nominations Committees. He has served as Chair of the Task Forces for writing clinical guidelines for the approach to acromegaly for both The Endocrine Society and the American Association of Clinical Endocrinologists. Dr. Katznelson has also served as Chair of the Clinical Investigator Workshop for the Endocrine Society. He is the recipient of the 2017 Laureate Award for Educator of the Year, The Endocrine Society. He is also the recipient of the H. Jack Baskin, Endocrine Teaching Award, AACE in 2015. Dr. Katznelson has a long standing clinical and research interest in the pathophysiology and treatment of pituitary disease.

Disclosures:

Research Grant Support, Chiasma Inc.; Advisory Board, Pfizer
The Journey: How to Proceed, the Decision Process
Shlomo Melmed, MB ChB
Cedars-Sinai Medical Center, Los Angeles, California, USA
Shlomo Melmed, MB ChB, is Executive Vice-President and Dean at Cedars-Sinai Medical Center and holds the Helene A. and Philip E. Hixon Chair in Investigative Medicine. He has been a recipient of the Endocrinology Medal of the Royal Society of Medicine, the Endocrine Society Clinical Investigator and Outstanding Scholarly Physician Awards, the Society of Endocrinology Transatlantic Medal, the Fondation IPSEN Endocrine Regulations Prize, and the Pituitary Society's Lifetime Achievement Award. Dr. Melmed’s research is devoted to molecular pathogenesis and treatment of pituitary tumors and growth factor regulation of anterior pituitary function. He edits The Pituitary and co-edits Williams Textbook of Endocrinology; he co-authors Harrison's Textbook of Medicine pituitary section, is editor-in-chief of Pituitary, and is on the editorial board of Journal of Clinical Investigation and past Editor-in-Chief of Endocrinology. He served on NIH Endocrinology Study Section, was president and founding member of the Pituitary Society, member of Endocrine Society Council and President of International Society of Endocrinology. He is Program Chair of the International Congress of Endocrinology, and a Board Member of the California Institute of Regenerative Medicine (CIRM).
Audience Q&A
All
We thank our educational partners, CMM Global, Inc.
supported by:
Chiasma, Inc.
 

Learning Objectives:

  • Examine the main aspects of acromegaly, including scientific advances and expanding knowledge of disease pathogenesis, improvements in disease management, and new medical therapies (available and in development) to improve disease control
  • Establish familiarity with current research related to patient and medical provider reporting of symptoms during treatment
  • Enhance understanding of available treatment options and the consequent outcomes (i.e., control of GH/IGF-I levels, amelioration of signs/symptoms, improved QoL, ease of administration) associated with use of these different treatment options
Ancillary Symposium: Hypophosphatemia: Unlocking The Key To Improved Diagnosis And Management
Not Currently Available
Introduction, Pre-Test Questions
Michael A. Levine, MD
Children Hospital of Philadelphia, Philadelphia, Pensylvania, USA
Dr. Levine is Chief Emeritus of Endocrinology and Diabetes and Director of the Center for Bone Health at The Children’s Hospital of Philadelphia. Dr. Levine holds the Lester Baker Endowed Chair and is Professor Emeritus of Pediatrics and Medicine at the University of Pennsylvania Perelman School of Medicine.

Dr. Levine’s research interests focus on the genetic basis of endocrine diseases that affect bone and mineral metabolism, particularly rickets, primary hyperparathyroidism, and hypoparathyroidism. Dr. Levine has published over 400 manuscripts, chapters, and reviews. He is a former Editor of the Journal of Clinical Endocrinology and Metabolism, and has served as a member of the Board of Directors of the U.S. Pediatric Endocrine Society.

He has received numerous awards in recognition of his accomplishments as a physician scientist, including the Distinguished Endocrinology Award from the American College of Endocrinology, the Frederic C. Bartter Award from the American Society of Bone and Mineral Research, and the International Award from the European Society for Pediatric Endocrinology.

Disclosures:

Research Investigator, Ultragenyx Pharmaceuticals
X-linked Hypophosphatemia Update: History and Future Goals of Treatment
Leanne M. Ward, MD
Unversity of Ottawa, Ottawa, Ontario, Canada
Leanne Ward is a Professor of Pediatrics at the University of Ottawa where she has held a Research Chair in Pediatric Bone Health since 2010. She is the Scientific Director of the Ottawa Pediatric Bone Health Research Group, the Medical Director of the Genetic and Metabolic Bone Disease Clinic at the Children’s Hospital of Eastern Ontario (CHEO), and a pediatric endocrinologist in the Division of Endocrinology and Metabolism at CHEO. Dr. Ward is also the Founder and Chair of the Canadian Consortium for Children’s Bone Health, a national working group dedicated to the care and study of children with bone disorders.
Leanne is actively involved in a number of clinical trials for children with bone fragility disorders such as osteogenesis imperfecta, rickets (including X-linked hypophosphatemia), and chronic illness osteoporosis. She has served as an endocrinology and bone health advisor to various international organizations including the Centres for Disease Control Clinical Care Considerations for Duchenne Muscular Dystrophy (DMD), the International Late Effects of Childhood Cancer Guideline Harmonization Group, the International Society for Clinical Densitometry, Soft Bones Canada, Parent Project Muscular Dystrophy, and the International Conference on Children’s Bone Health.
Dr. Ward has been the principal investigator of the “STOPP” research program (STeroid-associated Osteoporosis in the Pediatric Population) since 2003, a pan-Canadian project funded by the Canadian Institutes of Health Research to evaluate the effect of glucocorticoids on bone health in children with chronic illnesses. This multi-centre longitudinal research program has unveiled the natural history of osteoporotic fractures in children with steroid-treated disorders, including the clinical hallmark of this disorder in children, vertebral fractures. The results of the STOPP Consortium’s work under Dr. Ward’s leadership have played a major role in informing the approach to the diagnosis of steroid-induced osteoporosis in children, to the monitoring of those at risk, and in identifying children in need of osteoporosis prevention and intervention.
Dr. Ward has received a number of awards for her work in pediatric bone health, including a Canadian Child Health Clinician Scientist Career Development Award, a Canadian Institutes for Health Research New Investigator Award, a Canadian Child Health Clinician Scientist Career Enhancement Award, and three, five-year Research Chairs in Pediatric Bone Disorders from the University of Ottawa (2010, 2015, and 2020).
In 2019, Dr. Ward was named a Fellow of the American Society of Bone and Mineral Research, an award in recognition of significant contributions to the Society, and to bone and mineral science.
Tumor-Induced Osteomalacia Diagnosis and Tumor-Induced Osteomalacia Management and Therapeutic Goals
Michael A. Levine, MD
Children Hospital of Philadelphia, Philadelphia, Pensylvania, USA
Patient Case
Leanne M. Ward, MD
Unversity of Ottawa, Ottawa, Ontario, Canada
Audience Q&A
All
supported by:
Ultragenyx Pharmaceuticals
 

Learning Objectives:

  • Evaluate the pros and cons of different imaging techniques for identifying tumor-induced osteomalacia
  • Identify symptoms to encourage evaluation for phosphorous management
  • Discuss optimal approaches to XLH management
Ancillary Symposium: Keeping Sight of Thyroid Eye Disease
Not Currently Available
Overview of TED Pathophysiology
Terry J. Smith, MD
University of Michigan Medical School, Ann Arbor, Michigan, USA
Terry J. Smith, MD, the Frederick G.L. Huetwell Professor in Ophthalmology and Visual Sciences and Internal Medicine at the University of Michigan Medical School, studies Graves’ disease, its ocular manifestations, and related autoimmune diseases. Dr. Smith’s laboratory has described many unique molecular attributes of tissues surrounding the eye that make the orbit susceptible to inflammation and remodeling in Graves' disease. His investigation of these mechanisms has yielded several potential therapeutic targets that may interrupt the disease process. Among these, the insulin-like growth factor I receptor was implicated in the pathogenesis of thyroid-associated ophthalmopathy by his group and its inhibition has recently been shown to hold great therapeutic promise in thyroid-associated ophthalmopathy. Dr. Smith received his medical degree from the University of Missouri School of Medicine and completed his postdoctoral training at the University of California, San Francisco, Columbia University, and the University of Chicago. His laboratory has been supported continuously by the NIH and/or the VA for over 35 years.

Disclosures:

Consultant, Novartis, Merck, Lithera, Immunovant, River Vision, Horizon Therapeutics; Research Grant Support, NIH, NEI
Clinical Features: Improving Diagnosis
Don O. Kikkawa, MD
UC San Diego Health, La Jolla, California, USA
Don O. Kikkawa, MD, is Professor of Clinical Ophthalmology, Chief of the Division of Ophthalmic Plastic and Reconstructive Surgery, and Vice Chairman at the University of California at San Diego (UCSD) Department of Ophthalmology and UCSD Shiley Eye Institute in La Jolla. Dr. Kikkawa joined the UCSD Ophthalmology faculty in 1993 and is co-director of the UCSD Thyroid Eye Center and also a former program director of UCSD's ophthalmology residency. Dr. Kikkawa earned a BA (magna cum laude) in biochemistry from UCSD, La Jolla and an MD (magna cum laude) from St. Louis University School of Medicine, St. Louis, Missouri. He completed his internship at the UCSD, his residency at Jules Stein Eye Institute (UCLA) and a fellowship in Ophthalmic Plastic and Orbital Surgery at the University of Wisconsin, Madison. Dr. Kikkawa's clinical interests include aesthetic and reconstructive oculofacial surgery; orbital surgery; thyroid orbitopathy; craniofacial disorders involving the eyelids and orbits; and tumors.

Disclosures:

Consultant, Horizon Therapeutics; Book Royalties, Elsevier Publishing
Current and Emerging Therapeutic Landscape
Don O. Kikkawa, MD(Panelist)
UC San Diego Health, La Jolla, California, USA
Don O. Kikkawa, MD, is Professor of Clinical Ophthalmology, Chief of the Division of Ophthalmic Plastic and Reconstructive Surgery, and Vice Chairman at the University of California at San Diego (UCSD) Department of Ophthalmology and UCSD Shiley Eye Institute in La Jolla. Dr. Kikkawa joined the UCSD Ophthalmology faculty in 1993 and is co-director of the UCSD Thyroid Eye Center and also a former program director of UCSD's ophthalmology residency. Dr. Kikkawa earned a BA (magna cum laude) in biochemistry from UCSD, La Jolla and an MD (magna cum laude) from St. Louis University School of Medicine, St. Louis, Missouri. He completed his internship at the UCSD, his residency at Jules Stein Eye Institute (UCLA) and a fellowship in Ophthalmic Plastic and Orbital Surgery at the University of Wisconsin, Madison. Dr. Kikkawa's clinical interests include aesthetic and reconstructive oculofacial surgery; orbital surgery; thyroid orbitopathy; craniofacial disorders involving the eyelids and orbits; and tumors.
Terry J. Smith, MD(Panelist)
University of Michigan Medical School, Ann Arbor, Michigan, USA
Audience Q&A
All
supported by:
Horizon Therapeutics
 

Learning Objectives:

  • Describe the basic pathophysiology of Graves’ disease and thyroid eye disease
  • Analyze early signs and symptoms of thyroid eye disease, including criteria for stratifying mild, moderate, and severe disease, and determinants of disease activity
  • Evaluate new and emerging biological agents for treatment of thyroid eye disease